
Prevention Diagnosis Treatment
Research
Our path began in Guam, with a question about why two remote villages suffered so much neurological disease. We discovered that a neurotoxin in traditional foods was produced by cyanobacteria. This led to a possible new drug, and a new miRNA test that could change how quickly patients get help.
- Disease
ALS
Why diagnosis takes a year, and the ALS Test designed to change that.
Read - Diagnostics
Biomarkers
Blood tests for ALS and Alzheimer's, and why a faster diagnosis matters.
Read - Cause
Cyanobacteria and BMAA
The ancient bacteria behind a neurotoxin, from Guam to the Great Salt Lake.
Read - Treatment
L-serine
A dietary amino acid in clinical trials for ALS and mild cognitive impairment.
Read - Disease
MCI/Alzheimer’s Disease
A treatment window before Alzheimer's, an L-serine trial, and miRNA blood tests.
Read - Disease
Parkinson’s Disease
A naturally occurring molecule against alpha-synuclein misfolding, and a planned Phase II trial.
Read - Disease
Glioblastoma
Violet cyclotides that strengthen chemotherapy against a lethal brain cancer.
Read - Antiviral
Prostratin
An antiviral from a Samoan healer's remedy, and the benefit-sharing agreements behind it.
Read
- 01
Prevention
An environmental toxin.
We traced BMAA, a neurotoxin made by cyanobacteria, from the cycad roots of Guam into the brains of ALS and Alzheimer's patients. It slips into proteins in place of the amino acid L-serine and makes them misfold and tangle. Today we monitor it in the air over the Great Salt Lake and the waters of Florida.
Cyanobacteria and BMAA - 02
Diagnose
One blood draw.
It can take around 12 months to get an ALS diagnosis. Our blood test is based on a unique genetic fingerprint that differentiates people with ALS from healthy controls. Similar tests for Parkinson's, Alzheimer's, and Multiple Sclerosis are under development.
The ALS Test - 03
Treat
A naturally occurring amino acid.
In laboratory and animal studies, increasing L-serine prevented BMAA from being built into proteins. Our FDA-approved clinical trial of L-serine for Mild Cognitive Impairment at Houston Methodist is nearing completion, and separate Phase II trials will begin soon for ALS and Parkinson's disease.
L-serine trials
Our scientists are constrained by research funding, not capacity.
As a not-for-profit organization, we care only for patients, not profits.
Our innovative approach is working, but we need your support. Based on our 2025 audit, 81% of all gifts go to medical research.
